AOP Orphan und PharmaEssentia verkünden rezente Ergebnisse zu Ropeginterferon alfa-2b

AOP Orphan Pharmaceuticals AG
Dr. Christoph Klade, Chief Scientific Officer
Email: christoph.klade(at)
Tel: +43 503 72 44-24

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)